Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LA9K
|
|||
| Drug Name |
REGN4018
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ovarian carcinoma antigen CA125 (MUC16) | Target Info | Inhibitor | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03564340) Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer. U.S. National Institutes of Health. | |||
| REF 2 | A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.